June 27, 2022
The Pharmaceuticals and Medical Devices Agency (PMDA) is investigating a new side effect risk for AstraZeneca’s Imfinzi (durvalumab) and Merck Biopharma’s Bavencio (avelumab), both PD-L1 inhibitors, a move likely to trigger label changes in the near future. According to the...read more